-
October 19, 2022
The turnover from transactions with Bulgarian shares reached just under BGN 6 million, and two-thirds of it (just over BGN 4 million) was formed by transactions with shares of Tchaikapharma High Quality Medicines. Another 4 companies formed another quarter of the turnover, SOFIX recorded a minimal decrease. Read the full article here in Bulgarian.
-
October 5, 2022
Tchaikapharma has launched two new medicinal products on the market, which are already commercially available: Methylprednisolone-Chaikapharma (methylprednisolone) 40 mg powder and solvent for for injection solution TromBai (cilostazol) 100 mg tablets The distributor of the medicinal products is Commercial League – Global Pharmа Center.
-
July 8, 2022
On July 7, 2022, the Bulgarian Credit Rating Agency (BCRA) has awarded the company with the highest market capitalization on the Bulgarian Stock Exchange Tchaikapharma a long-term credit rating of “BBB-” and a short-term “A” on a national scale. With this, BCRA expresses its opinion that the company maintains a very good financial position with […]
-
July 4, 2022
“Politicians in power have one main task – to create a competitive investment and business environment and deal with the growth of the national economy. The self-esteem of any nation is a product of GDP per capita. Politicians should focus on this issue.” This is what Tihomir Kamenov, a specialist in public and private law, […]
-
June 13, 2022
Tchaikapharma has expanded its portfolio with another product, namely Fluidoro 10 mg film-coated tablets (with active ingredient prasugrel). It belongs to a group of drugs called platelet antiaggregants – it inhibits the accumulation of platelets and thus reduces the risk of blood clots. Fluidoro, given concomitantly with acetylsalicylic acid (ASA), is indicated for the […]